TP53Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

MLA

Shah, Mithun V., et al. “TP53Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome.” Blood, vol. 140, no. 1, Number 1 Supplement 1, Nov. 2022, pp. 9798–99. EBSCOhost, https://doi.org/10.1182/blood-2022-165859.

APA

Shah, M. V., Hahn, C. N., Tran, E. N. H., Sharplin, K. M., Chhetri, R., Baranwal, A., Kutyna, M. M., Wang, P., Ladon, D., Al-Kali, A., Alkhateeb, H. B., Ross, D. M., Yeung, D. T., Shanmuganathan, N., Litzow, M. R., Mangaonkar, A. A., Hogan, W. J., Gangat, N., Patnaik, M. M. M., … Hiwase, D. (2022). TP53Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome. Blood, 140(1, Number 1 Supplement 1), 9798–9799. https://doi.org/10.1182/blood-2022-165859

Chicago

Shah, Mithun V., Christopher N Hahn, Elizabeth Ngoc Hoa Tran, Kirsty M Sharplin, Rakchha Chhetri, Anmol Baranwal, Monika M Kutyna, et al. 2022. “TP53Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome.” Blood 140 (1, Number 1 Supplement 1): 9798–99. doi:10.1182/blood-2022-165859.